Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis

Joselle Cook; Wilson I. Gonsalves; Morie A. Gertz; Alissa Visram; Rahma Warsame; Martha Q. Lacy; Angela Dispenzieri; David Dingli; Prashant Kapoor; Taxiarchis V. Kourelis; Suzanne R. Hayman; Robert A. Kyle; Eli Muchtar; Shaji K. Kumar; William J. Hogan; Eapen K. Jacob; Francis K. Buadi

doi:10.1038/s41409-022-01659-w

Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis

Joselle Cook, Wilson I. Gonsalves, Morie A. Gertz, Alissa Visram, Rahma Warsame, Martha Q. Lacy, Angela Dispenzieri, David Dingli, Prashant Kapoor, Taxiarchis V. Kourelis, Suzanne R. Hayman, Robert A. Kyle, Eli Muchtar, Shaji K. Kumar, William J. Hogan, Eapen K. Jacob, Francis K. Buadi

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1007-1009
Number of pages	3
Journal	Bone Marrow Transplantation
Volume	57
Issue number	6
DOIs	https://doi.org/10.1038/s41409-022-01659-w
State	Published - Jun 2022

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-022-01659-w

Cite this

Cook, J., Gonsalves, W. I., Gertz, M. A., Visram, A., Warsame, R., Lacy, M. Q., Dispenzieri, A., Dingli, D., Kapoor, P., Kourelis, T. V., Hayman, S. R., Kyle, R. A., Muchtar, E., Kumar, S. K., Hogan, W. J., Jacob, E. K., & Buadi, F. K. (2022). Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 57(6), 1007-1009. https://doi.org/10.1038/s41409-022-01659-w

Cook, J, Gonsalves, WI , Gertz, MA, Visram, A, Warsame, R, Lacy, MQ , Dispenzieri, A , Dingli, D , Kapoor, P , Kourelis, TV, Hayman, SR, Kyle, RA, Muchtar, E, Kumar, SK , Hogan, WJ, Jacob, EK & Buadi, FK 2022, 'Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis', Bone Marrow Transplantation, vol. 57, no. 6, pp. 1007-1009. https://doi.org/10.1038/s41409-022-01659-w

@article{a1f89af712ee4ad28d0cb027cff1cb7e,

title = "Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis",

author = "Joselle Cook and Gonsalves, {Wilson I.} and Gertz, {Morie A.} and Alissa Visram and Rahma Warsame and Lacy, {Martha Q.} and Angela Dispenzieri and David Dingli and Prashant Kapoor and Kourelis, {Taxiarchis V.} and Hayman, {Suzanne R.} and Kyle, {Robert A.} and Eli Muchtar and Kumar, {Shaji K.} and Hogan, {William J.} and Jacob, {Eapen K.} and Buadi, {Francis K.}",

note = "Funding Information: AD: Alnylam: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Takeda: Research Funding; Intellia: Research Funding; Pfizer: Research Funding. DD: Grant/Research funding from Juno, Celgene. MG: personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, and Celgene personal fees from Research to Practice, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health. Educational Program development i3Health. Royalties from Springer Publishing. Grant Funding Amyloidosis Foundation; International Waldenstrom Foundation. NCI SPORE MM SPORE 5P50 CA186781-04 PK: Research funding (Takeda, Celgene, and Amgen). SK: Consulting or advisory Role with Takeda, Janssen Oncology, Amgen, AbbVie, Merck, Celgene, Genentech/Roche, Oncopeptides, Kite, a Gilead company, Genecentrix, Molecular Partners, Bluebird Bio, Cellectar and research Funding: Celgene, Takeda, AbbVie, Novartis, Sanofi, Janssen Oncology, Merck, Kite, a Gilead company, MedImmune, Roche/Genentech, TeneoBio, CARsgen Therapeutics. MQL: Research funding (Celgene) ",

year = "2022",

month = jun,

doi = "10.1038/s41409-022-01659-w",

language = "English (US)",

volume = "57",

pages = "1007--1009",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis

AU - Cook, Joselle

AU - Gonsalves, Wilson I.

AU - Gertz, Morie A.

AU - Visram, Alissa

AU - Warsame, Rahma

AU - Lacy, Martha Q.

AU - Dispenzieri, Angela

AU - Dingli, David

AU - Kapoor, Prashant

AU - Kourelis, Taxiarchis V.

AU - Hayman, Suzanne R.

AU - Kyle, Robert A.

AU - Muchtar, Eli

AU - Kumar, Shaji K.

AU - Hogan, William J.

AU - Jacob, Eapen K.

AU - Buadi, Francis K.

N1 - Funding Information: AD: Alnylam: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Takeda: Research Funding; Intellia: Research Funding; Pfizer: Research Funding. DD: Grant/Research funding from Juno, Celgene. MG: personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, and Celgene personal fees from Research to Practice, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health. Educational Program development i3Health. Royalties from Springer Publishing. Grant Funding Amyloidosis Foundation; International Waldenstrom Foundation. NCI SPORE MM SPORE 5P50 CA186781-04 PK: Research funding (Takeda, Celgene, and Amgen). SK: Consulting or advisory Role with Takeda, Janssen Oncology, Amgen, AbbVie, Merck, Celgene, Genentech/Roche, Oncopeptides, Kite, a Gilead company, Genecentrix, Molecular Partners, Bluebird Bio, Cellectar and research Funding: Celgene, Takeda, AbbVie, Novartis, Sanofi, Janssen Oncology, Merck, Kite, a Gilead company, MedImmune, Roche/Genentech, TeneoBio, CARsgen Therapeutics. MQL: Research funding (Celgene)

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85127582153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127582153&partnerID=8YFLogxK

U2 - 10.1038/s41409-022-01659-w

DO - 10.1038/s41409-022-01659-w

M3 - Letter

C2 - 35368041

AN - SCOPUS:85127582153

SN - 0268-3369

VL - 57

SP - 1007

EP - 1009

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 6

ER -

Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this